Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations

Figure 1

Proteasome inhibitor bortezomib induces massive cell killing in endometrial cancer cells with TP53 GOF mutation R175H (KLE cells) but not LOF mutation (Hec50 cells). All experiments were performed three times. IC50: KLE cells, 2.1 ± 0.3 nM; Hec50 cells, 19.4 ± 1.0 nM; by Student’s -test.